We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Effect of cross-platform gene-expression, computational methods on breast cancer subtyping in PALOMA-2 and PALLET studies.
- Authors
Cheang, Maggie Chon U.; Rimawi, Mothaffar; Johnston, Stephen; Jacobs, Samuel A.; Bliss, Judith; Pogue-Geile, Katherine; Kilburn, Lucy; Zhu, Zhou; Schuster, Eugene F.; Xiao, Hui; Swaim, Lisa; Deng, Shibing; Lu, Dongrui R.; Gauthier, Eric; Tursi, Jennifer; Slamon, Dennis J.; Rugo, Hope S.; Finn, Richard S.; Liu, Yuan
- Abstract
Intrinsic breast cancer molecular subtyping (IBCMS) provides significant prognostic information for patients with breast cancer and helps determine treatment. This study compared IBCMS methods on various gene-expression platforms in PALOMA-2 and PALLET trials. PALOMA-2 tumor samples were profiled using EdgeSeq and nanostring and subtyped with AIMS, PAM50, and research-use-only (ruo)Prosigna. PALLET tumor biopsies were profiled using mRNA sequencing and subtyped with AIMS and PAM50. In PALOMA-2 (n = 222), a 54% agreement was observed between results from AIMS and gold-standard ruoProsigna, with AIMS assigning 67% basal-like to HER2-enriched. In PALLET (n = 224), a 69% agreement was observed between results from PAM50 and AIMS. Different IBCMS methods may lead to different results and could misguide treatment selection; hence, a standardized clinical PAM50 assay and computational approach should be used. Trial number: NCT01740427
- Subjects
BREAST cancer; CANCER patients
- Publication
NPJ Breast Cancer, 2024, Vol 10, Issue 1, p1
- ISSN
2374-4677
- Publication type
Article
- DOI
10.1038/s41523-024-00658-y